GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study ...

Centricity Research celebrated the opening of its new clinical research facility at 910 Talbotton Rd. in Columbus, Georgia on ...

Enrollment of healthy volunteers for a Phase 1 trial testing Duchenne muscular dystrophy (DMD) treatment candidate SAT-3247 ...

Efforts by the Trump administration to drastically cut federal investments in medical research are threatening to kneecap ...

Yet, this lack of bespoke options is more or less the reality of medicine today. Despite the many biological differences between people of different genders, races, ages and life histories, chances ...

The E.mbrace study is a randomized, double-blind, placebo-controlled, multicenter, interventional phase 3 study evaluating the efficacy, safety, and immunogenicity of a single dose of the vaccine ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...